- Conditions
- Type 2 Diabetes
- Interventions
- Nateglinide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 28 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Insulin Resistance, Type 2 Diabetes Mellitus
- Interventions
- pioglitazone, nateglinide, placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 55 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2006
- U.S. locations
- 2
- States / cities
- Seattle, Washington • Tacoma, Washington
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 9,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- Multiple Locations, New Jersey
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey